Outcomes of neonates conceived on methadone maintenance therapy

McCarthy, John J.; Leamon, Martin H.; Stenson, Garrett; Biles, Lagen A.

doi:10.1016/j.jsat.2007.09.009

Cited by 19 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While such findings are counterintuitive, many of the patients entered substance abuse treatment concurrent with beginning participation in the study, therefore days of maternal medication may, in fact, reflect the length of time the mother received comprehensive substance abuse treatment and prenatal care and reduced her concomitant illicit drug use. It is also consistent with previous findings that babies conceived on methadone do not exhibit more severe neonatal abstinence than infants exposed to methadone for only part of the gestational period , and that longer maternal methadone treatment correlates with better birth outcomes .…”

Section: Discussionsupporting

confidence: 92%

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

et al. 2012

View full text Add to dashboard Cite

Aim To identify factors that predict the expression of neonatal abstinence syndrome (NAS) in infants exposed to methadone or buprenorphine in utero. Design and Setting Multi-site randomized clinical trial in which infants were observed for a minimum of 10 days following birth, and assessed for NAS symptoms by trained raters. Participants n = 131 infants born to opioid dependent mothers, 129 of which were available for NAS assessment. Measurements Generalized linear modeling was performed using maternal and infant characteristics to predict: peak NAS score prior to treatment, whether an infant required NAS treatment, length of NAS treatment, and total dose of morphine required for treatment of NAS symptoms. Findings 53% of the sample (68 infants) required treatment for NAS. Lower maternal weight at delivery, later estimated gestational age (EGA), maternal use of selective serotonin reuptake inhibitors (SSRIs), vaginal delivery, and higher infant birth weight predicted higher peak NAS scores. Higher infant birth weight and greater maternal nicotine use at delivery predicted receipt of NAS treatment for infants. Maternal use of SSRIs, higher nicotine use, and fewer days of study medication received also predicted total dose of medication required to treat NAS symptoms. No variables predicted length of treatment for NAS. Conclusions Maternal weight at delivery, estimated gestational age, infant birth weight, delivery type, maternal nicotine use, and days of maternal study medication received, and the use of psychotropic medications in pregnancy may play a role in the expression of neonatal abstinence syndrome severity in infants exposed to either methadone or buprenorphine.

show abstract

Section: Discussionsupporting

confidence: 92%

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In our study, only 14 women, less than 25% of the whole cohort, were already in MMT before conception. McCarthy et al (2008) compared babies of women who were in MMT from the 1st pregnancy trimester to those who were in MMT only from the 2nd or 3rd trimesters, and found no differences in neonatal outcome (birth weight, gestational age at delivery, neonatal abstinence syndrome duration, and hospitalization) between the groups. Like us, they found that those who were in MMT from the 1st trimester had less illicit drug abuse at delivery than those admitted during the 2nd or 3rd trimesters.…”

Section: Discussionmentioning

confidence: 99%

Duration of Methadone Maintenance Treatment During Pregnancy and Pregnancy Outcome Parameters in Women With Opiate Addiction

Peles

Schreiber

Bloch

et al. 2012

Journal of Addiction Medicine

View full text Add to dashboard Cite

show abstract

“…Ensuing disputes about whether buprenorphine should be recommended as 'the drug of choice' for pregnant women highlighted tensions between whose body we should be caring about most and what 'risks' we should be prioritisingmothers or babies? (McCarthy, Leamon, Stenson, & Biles, 2008).…”

Section: Nas: Attitudes and Approaches To Maternal Drug Use During Prmentioning

confidence: 99%

Problematisation and regulation: Bodies, risk, and recovery within the context of Neonatal Abstinence Syndrome

Whittaker

Chandler

Cunningham‐Burley

et al. 2019

International Journal of Drug Policy

View full text Add to dashboard Cite

Differing notions of risk and recovery that govern maternal drug use, child welfare and family life both compel and trouble all logics of care. The contentious nature of NAS reflects wider socio-political and moral agendas that ultimately have little to do with meeting the needs of mothers and babies. Fundamental changes in the principles, quality and delivery of care could improve outcomes for families affected by NAS.

show abstract

Outcomes of neonates conceived on methadone maintenance therapy

Cited by 19 publications

References 23 publications

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication

Duration of Methadone Maintenance Treatment During Pregnancy and Pregnancy Outcome Parameters in Women With Opiate Addiction

Problematisation and regulation: Bodies, risk, and recovery within the context of Neonatal Abstinence Syndrome

Contact Info

Product

Resources

About